TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00508014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care with primary care provider during time period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Peer Review visit
Description: Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
Study: NCT04028050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
Study: NCT03408938

Intervention type: DEVICE
Intervention: of Masimo Radical-7¿ Pulse CO-Oximeter
Description: The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm
Study: NCT03950830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 400mg daily, continuously
Study: NCT02245399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A canola oil enriched mediterranean diet
Description: The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A high wheat fiber diet
Description: The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
Study: NCT04630002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/RTV)
Description: DRV/RTV will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/RTV)
Description: DRV/RTV will be available as oral tablets.
Study: NCT02640326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Foley Urinary Catheter
Description: No Foley urinary catheter will be put in place during the operation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care Foley urinary catheter insertion
Description: A Foley urinary catheter will be put in place during the operation
Study: NCT04630002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR will be available as oral tablets.
Study: NCT01223118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification and PGD
Description: Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
Study: NCT04451057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula therapy
Description: Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low flow nasal cannula therapy
Description: Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
Study: NCT00171210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Tablets taken orally once a day.
Study: NCT02479451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: The study medication will be provided by Foundation Care.
Study: NCT00031590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Radiation
Description: Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
Study: NCT03334344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceevra Reveal
Description: VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
Study: NCT03830697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Description: Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture intervention
Description: Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).
Study: NCT05628935

Intervention type: PROCEDURE
Intervention: peripheral nerve block
Description: local anesthetic application to the brachial plexus
Study: NCT01856127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
Study: NCT03589898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Single dose of gabapentin 900 mg
Study: NCT03160027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vielight Neuro Gamma
Description: The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
Study: NCT03080519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Therapy
Description: Balloon angioplasty and stenting for renal artery stenosis
Study: NCT01910129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore
Description: vagal verve stimulation 3 times a day 8 hours apart

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: gammaCore
Description: vagal verve stimulation 3 times a day 8 hours apart
Study: NCT04050761

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Specified dose on Specific Days
Study: NCT01624571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD02GIFRO
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD02GIFRO
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD02GIFRO
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LD02GIFRO
Description: comparison of different dosages of drug
Study: NCT02655822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: 100 mg orally twice daily for the first 14 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: 100 mg orally twice daily for 28 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: 200 mg orally once daily for the first 14 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant + atezolizumab
Description: Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
Study: NCT00971438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic imaging
Description: Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic imaging
Description: Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
Study: NCT01772173

Intervention type: OTHER
Intervention: Vessel measurements
Description: Measurement of retinal vessels
Study: NCT03283566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
Study: NCT01641458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype
Description: Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G\>A, c.1679T\>G, HapB3/c.1129-5923C\>G and c.2846A\>T).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of 5FU
Description: Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
Study: NCT01096719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss Intervention
Description: 12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss Intervention
Description: 12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention
Description: 12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Goal: Reduction in Energy Density of Dietary Intake
Description: Consume low ED foods (ED \< 1.0) for at least 10 items consumed per day and limit high ED foods (ED \> 3.0) to two items consumed per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Goal: Reduction in Energy Density of Dietary Intake
Description: Consume low ED foods (ED \< 1.0) for at least 10 items consumed per day and limit high ED foods (ED \> 3.0) to two items consumed per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Goal: Reduction of Energy Intake
Description: Limit energy intake to 1200 to 1500 kcals/day and \< 30% kcals from fat.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Goal: Reduction of Energy Intake
Description: Limit energy intake to 1200 to 1500 kcals/day and \< 30% kcals from fat.
Study: NCT00865228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
Study: NCT03005704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment
Description: Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
Study: NCT03747380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle program
Description: pre-operative inspiratory muscular training program

Intervention type: OTHER
Group type: OTHER
Intervention: inspiratory muscle program
Description: pre-operative inspiratory muscular training program
Study: NCT01590225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks.
Study: NCT02569801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
Study: NCT01579097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oliclinomel N4
Description: Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compounded ternary parenteral nutrition admixtures
Description: Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
Study: NCT03386552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isifera+
Description: Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffer
Description: Pertubation solution of Ringer-Acetate buffer
Study: NCT03771911

Intervention type: DEVICE
Group type: OTHER
Intervention: AED
Description: Instructions provided by an AED
Study: NCT04236310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
Study: NCT03771911

Intervention type: DEVICE
Group type: OTHER
Intervention: AED
Description: Instructions provided by an AED

Intervention type: DEVICE
Group type: OTHER
Intervention: Telephone
Description: Instructions provided by emergency Call Center (telephonically) with the help of an AED.
Study: NCT01088763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study: NCT01928472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9c low dose with adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9c medium dose with adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9c high dose with adjuvant
Study: NCT04236310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400mg once daily for 16 weeks
Study: NCT01928472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9c high dose without adjuvant
Study: NCT01237574

Intervention type: OTHER
Intervention: Intervention according to the standard of care.
Description: Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.